References
- Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD (1997). Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood, 89, 2067-78.
- de Boer CJ, Schuuring E, Dreef E, et al (1995). Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood, 86, 2715-23.
- Bosch F, Lopez-Guillermo A, Campo, E et al (1998). Mantle cell lymphoma. Cancer, 82, 567-75. https://doi.org/10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO;2-Z
- Cheson BD, Pfistner B, Juweid ME, et al (2007). Revised Response Criteria for Malignant Lymphoma. J Clin Oncol, 25, 579-86. https://doi.org/10.1200/JCO.2006.09.2403
- Delarue R, Haioun C, Ribrag V, et al (2013). CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood, 121, 48-53. https://doi.org/10.1182/blood-2011-09-370320
- Dreyling M, Lenz G, Hoster E, et al (2005). Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood, 105, 2677-84. https://doi.org/10.1182/blood-2004-10-3883
- Geisler CH, Kolstad A, Laurell A, et al (2010). The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 115, 530-3. https://doi.org/10.1182/blood-2009-08-236521
- Hoster E, Dreyling M, Klapper W, et al (2008). A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.Blood, 111, 558-65. https://doi.org/10.1182/blood-2007-06-095331
- Li J-Y, Gaillard F, Moreau A, et al (1999). Detection of Translocation t(11;14)(q13;q32) in Mantle Cell Lymphoma by Fluorescence in Situ Hybridization. Am J Pathol,154,1449-52. https://doi.org/10.1016/S0002-9440(10)65399-0
- Martin P, Chadburn A, Christos P, et al (2009). Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol, 27,1209-13. https://doi.org/10.1200/JCO.2008.19.6121
- Mozos A, Royo C, Hartmann E, et al (2009). SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica, 94, 1555-62. https://doi.org/10.3324/haematol.2009.010264
- Naresh KN, Srinivas V, Soman CS (2000). Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Ann Oncol, 1, 63-7.
- Romaguera JE, Fayad L, Rodriguez MA, et al (2005). High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol , 23, 7013-23. https://doi.org/10.1200/JCO.2005.01.1825
- Swerdlow SH, Campo E, Pileri SA, et al (2016). The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood, 1, 569-643.
- Howlader N, Noone AM, Krapcho M et al 2015. In SEER Cancer Statistics Review, 1975-2013,Eds Cronin KA National Cancer Institute. Bethesda, MD.
- NCCN clinical practice guideline on NHL version 3.2016 [Internet]. [cited 2016b Jul 3]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf